(Q40122018)

17 September 2017

title

Pharmacokinetic/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren (English)

1 reference

17 September 2017

0 references

1 reference

1 reference

Y Hong

1

1 reference

17 September 2017

J Dingemanse

series ordinal

2

1 reference

17 September 2017

D E Mager

series ordinal

3

1 reference

17 September 2017

language of work or name

English

0 references

publication date

20 February 2008

1 reference

Clinical Pharmacology & Therapeutics

17 September 2017

published in

1 reference

17 September 2017

volume

84

1 reference

17 September 2017

issue

1

1 reference

17 September 2017

page(s)

136-143

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100495

17 September 2017

exact match

0 references

cites work

Dose-Dependent Effects of the Renin Inhibitor Zankiren HCl After a Single Oral Dose in Mildly Sodium-Depleted Normotensive Subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

Mortality by cause for eight regions of the world: Global Burden of Disease Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Drugs targeting the renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

The preparation, purification, and amino acid sequence of a polypeptide renin substrate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Structure-based design of aliskiren, a novel orally effective renin inhibitor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Renin inhibition with aliskiren: where are we now, and where are we going?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Diurnal change in plasma atrial natriuretic peptide concentrations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Pharmacologic target-mediated drug disposition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Target-mediated drug disposition and dynamics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

General pharmacokinetic model for drugs exhibiting target-mediated drug disposition

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560A in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Specific measurement of angiotensin metabolites and in vitro generated angiotensin II in plasma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Model-based drug development

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

The future of antihypertensive treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Assessment of antihypertensive activity in the regulatory setting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CLPT.6100495

7 January 2021

Identifiers

DOI

10.1038/SJ.CLPT.6100495

1 reference

Dimensions Publication ID

17 September 2017

1047598759

0 references

1 reference